Briacell Therapeutics Corp. Common Shares closed at $3.26 on Nov 4, up 8.31%, 74.2% below its 52-week closing high. Volume of 49.3K shares was 0.85× its 20-day average (close to normal).
Split-adjusted performance: -18.9% over one month, -21.4% over six months, -67.4% over one year.
Short interest was 789.5K shares at the Oct 15 settlement, up 1.3% from the prior report (9.3% of float, 14.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BCTXBriacell Therapeutics | $3.26 | +8.31% | −21.4% | — | — | — | $28.5M | |
| PMNProMIS Neurosciences Inc. Common Shares (ON) | $3.18 | −6.89% | −71.1% | — | — | — | $28.5M | Compare |
| BYSIBeyondSpring | $0.6856 | +10.40% | −55.8% | — | — | — | $28.2M | Compare |
| ACETAdicet Bio | $3.08 | −2.84% | −64.0% | — | — | — | $28.8M | Compare |
| NXTCNextCure | $6.05 | +2.37% | −43.6% | — | — | — | $27.7M | Compare |
| CELUCelularity | $0.8501 | +4.04% | −8.6% | −5.3% | 10.1% | — | $27.6M | Compare |
| FLNAFilana Therapeutics | $0.5697 | −4.14% | — | — | — | — | $27.5M | Compare |
| RNAZTransCode Therapeutics | $1.57 | 0.00% | −79.1% | — | — | — | $26.6M | Compare |
| AARDAardvark Therapeutics | $1.21 | −1.63% | −79.5% | — | — | — | $26.5M | Compare |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
